Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals Jan 22, 2020
Ocuphire Pharma Announces Completion of the First of Two Phase 2b Clinical Trials for Nyxol® Eye Drops Sep 4, 2019
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development Aug 7, 2019
Ocuphire Pharma Raises Over $5 Million to Complete Multiple Late Phase 2 Clinical Trials Jul 22, 2019
Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China Apr 16, 2019